Ukrainian Firm To Receive mRNA Tech Transfer From WHO Hub
Executive Summary
The Ukrainian pharma firm Darnitsa, which is the latest firm to benefit from the WHO’s mRNA coronavirus vaccine initiative, says it is continuing production amidst the continuing Russian attacks on the country. Meanwhile, the European Medicines Agency has issued guidance for sponsors on methodological aspects of trials affected by the war.
You may also be interested in...
WHO Inaugurates South African mRNA Technology Hub
More than 200 people took part in a meeting to assess progress with an mRNA technology transfer program that is intended to give manufacturers in lower-income countries the ability to produce and sell their own vaccines for COVID-19 and other diseases.
How To Transfer Clinical Trial Participants From Ukraine To EU Sites
An EU expert group and a number of member state agencies have published advice on the practicalities of safely moving Ukrainian clinical trial subjects to sites in EU and European Economic Area countries.
Coronavirus Notebook: Six African Countries To Produce mRNA Vaccines, CEPI Funds Indian Candidates
Alvea, a US biotech startup, says its first two DNA vaccine candidates are undergoing “rigorous” preclinical testing and could enter clinical trials as early as April this year.